Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult
NCT02553837 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 317
Last updated 2016-02-02
Summary
This study was aimed to evaluate the Immunogenicity and Safety response by vaccinating Hantavax in Healthy Adult.
Conditions
- Healthy
Interventions
- BIOLOGICAL
-
Hantavax injection
A single 0.5mL dose intramuscular or subcutaneous injection
Sponsors & Collaborators
-
Green Cross Corporation
lead INDUSTRY
Principal Investigators
-
Woo Joo Kim, MD · Korea University Guro Hospital
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2017-08-31
- Completion
- 2022-07-31
More Related Trials
-
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
NCT02979639 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
NCT01015703 ·Status: COMPLETED ·Phase: PHASE1
-
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
NCT02075515 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
NCT06961721 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
NCT05856084 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
NCT02869672 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of JNJ-64300535 in Healthy Participants
NCT04736147 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Anthrax Vaccine, GC1109
NCT01867957 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
NCT04869982 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
NCT02581410 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT06375512 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children
NCT02965404 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
NCT00397943 ·Status: COMPLETED ·Phase: PHASE2
-
Performance and Safety Evaluation of an Intradermal Delivery Device
NCT01359111 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
NCT01624532 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
NCT06137755 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
NCT02045836 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
NCT02114333 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT05701800 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
NCT05076227 ·Status: COMPLETED
-
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
NCT00534248 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
NCT06581575 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
NCT03314103 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607 ·Status: TERMINATED ·Phase: PHASE1/PHASE2